PMID- 36737048
OWN - NLM
STAT- MEDLINE
DCOM- 20230330
LR  - 20230919
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 10
IP  - 2
DP  - 2023 Apr
TI  - Comparison of care and outcomes for myocardial infarction by heart failure status 
      between United Kingdom and Japan.
PG  - 1372-1384
LID - 10.1002/ehf2.14290 [doi]
AB  - AIMS: Prognosis for ST-segment elevation myocardial infarction (STEMI) is worse 
      when heart failure is present on admission. Understanding clinical practice in 
      different health systems can identify areas for quality improvement initiatives 
      to improve outcomes. In the absence of international comparison studies, we aimed 
      to compare treatments and in-hospital outcomes of patients admitted with ST 
      elevation myocardial infarction (STEMI) by heart failure status in two 
      healthcare-wide cohorts. METHODS AND RESULTS: We used two nationwide databases to 
      capture admissions with STEMI in the United Kingdom (Myocardial ischemia National 
      Audit Project, MINAP) and Japan (Japanese Registry of All Cardiac and Vascular 
      Diseases-Diagnostic Procedure Combination, JROAD-DPC) between 2012 and 2017. 
      Participants were stratified using the HF Killip classification into three 
      groups; Killip 1: no congestive heart failure, Killip 2-3: congestive heart 
      failure, Killip 4: cardiogenic shock. We calculated crude rate and case mix 
      standardized risk ratios (CSRR) for use of treatments and in-hospital death. 
      Patients were younger in the United Kingdom (65.4 [13.6] vs. 69.1 [13.0] years) 
      and more likely to have co-morbidities in the United Kingdom except for diabetes 
      and hypertension. Japan had a higher percentage of heart failure and cardiogenic 
      shock patients among STEMI during admission than that in the United Kingdom. 
      Primary percutaneous coronary intervention (pPCI) rates were lower in the United 
      Kingdom compared with Japan, especially for patients presenting with Killip 2-3 
      class heart failure (pPCI use in patients with Killip 1, 2-3, 4: Japan, 86.2%, 
      81.7%, 78.7%; United Kingdom, 79.6%, 58.2% and 79.9%). In contrast, beta-blocker 
      use was consistently lower in Japan than in the United Kingdom (61.4% vs. 90.2%) 
      across Killip classifications and length of hospital stay longer (17.0 [9.7] vs. 
      5.0 [7.4] days). The crude rate of in-hospital mortality increased with 
      increasing Killip class group. Both the crude rate and CSRR was higher in the 
      United Kingdom compared with Japan for Killip 2-3 (15.8% vs. 6.4%, CSRR 1.80 95% 
      CI 1.73-1.87, P < 0.001), and similar for Killip 4 (36.9% vs. 36.3%, CSRR 1.11 
      95% CI 1.08-1.13, P < 0.001). CONCLUSIONS: Important differences in the care and 
      outcomes for STEMI with heart failure exist between the United Kingdom and Japan. 
      Specifically, in the United Kingdom, there was a lower rate of pPCI, and in 
      Japan, fewer patients were prescribed beta blockers and hospital length of stay 
      was longer. This international comparison can inform targeted quality improvement 
      programmes to narrow the outcome gap between health systems.
CI  - (c) 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of European Society of Cardiology.
FAU - Nakao, Kazuhiro
AU  - Nakao K
AUID- ORCID: 0000-0002-9034-3976
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, UK.
AD  - Leeds Institute of Data Analytics, University of Leeds, Leeds, UK.
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
FAU - Dafaalla, Mohamed
AU  - Dafaalla M
AD  - Keele Cardiovascular Research Group, Institute for Prognosis Research, University 
      of Keele, Newcastle upon Tyne, UK.
FAU - Nakao, Yoko M
AU  - Nakao YM
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, UK.
AD  - Leeds Institute of Data Analytics, University of Leeds, Leeds, UK.
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
FAU - Wu, Jianhua
AU  - Wu J
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, UK.
AD  - Leeds Institute of Data Analytics, University of Leeds, Leeds, UK.
AD  - School of Dentistry, University of Leeds, Leeds, UK.
FAU - Nadarajah, Ramesh
AU  - Nadarajah R
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, UK.
AD  - Leeds Institute of Data Analytics, University of Leeds, Leeds, UK.
AD  - Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Rashid, Muhammad
AU  - Rashid M
AD  - Keele Cardiovascular Research Group, Institute for Prognosis Research, University 
      of Keele, Newcastle upon Tyne, UK.
FAU - Mohammad, Haris
AU  - Mohammad H
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, UK.
AD  - Leeds Institute of Data Analytics, University of Leeds, Leeds, UK.
AD  - Department of Cardiology, Blackpool Teaching Hospitals NHS Trust, Blackpool, UK.
FAU - Sumita, Yoko
AU  - Sumita Y
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
FAU - Nakai, Michikazu
AU  - Nakai M
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
FAU - Iwanaga, Yoshitaka
AU  - Iwanaga Y
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
FAU - Miyamoto, Yoshihiro
AU  - Miyamoto Y
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
FAU - Noguchi, Teruo
AU  - Noguchi T
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
FAU - Yasuda, Satoshi
AU  - Yasuda S
AD  - National Cerebral and Cardiovascular Center, Suita, Japan.
AD  - Tohoku University Graduate School of Medicine, Sendai, Japan.
FAU - Ogawa, Hisao
AU  - Ogawa H
AD  - Kumamoto University, Kumamoto, Japan.
FAU - Mamas, Mamas A
AU  - Mamas MA
AD  - Keele Cardiovascular Research Group, Institute for Prognosis Research, University 
      of Keele, Newcastle upon Tyne, UK.
FAU - Gale, Chris P
AU  - Gale CP
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, UK.
AD  - Leeds Institute of Data Analytics, University of Leeds, Leeds, UK.
AD  - Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230203
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
RN  - 0 (Adrenergic beta-Antagonists)
SB  - IM
MH  - Humans
MH  - Shock, Cardiogenic
MH  - *ST Elevation Myocardial Infarction/epidemiology/therapy/diagnosis
MH  - Hospital Mortality
MH  - Japan/epidemiology
MH  - *Myocardial Infarction/diagnosis
MH  - *Heart Failure/epidemiology/therapy/diagnosis
MH  - Adrenergic beta-Antagonists
PMC - PMC10053358
OTO - NOTNLM
OT  - Heart failure
OT  - Medications
OT  - Mortality
OT  - ST elevation myocardial infarction
COIS- The following authors reports disclosures outside the submitted work. Y.M.A. 
      reports grants and personal fees from Bayer outside the submitted work. S.Y. 
      reports grants from Abbott Medical Japan, Amicus Therapeutics, Otsuka 
      Pharmaceutical, Kowa Company, Sumitomo Dainippon Pharma, Roche Diagnostics, 
      personal fee from Daiichi Sankyo and Bayer outside the submitted work. H.O. 
      reports personal fee from Bayer, Novartis, Bristol-Meyers Squibb, Daiichi Sankyo, 
      Pfizer, Eisai, Behringer Ingelheim, Takeda Pharmaceutical, Towa Pharmaceutical, 
      Toa Eiyo, Teijin, Abbott Medical Japan, Kowa Pharmaceuticals outside the 
      submitted work. C.P.G. reports grants from British Heart Foundation, Horizon 
      2020, Bristol Myers Squibb, National Institute for Health Research and Abbott 
      Diabetes, personal fees from AstraZeneca, Bristol Myers Squibb, Boston 
      Scientific, Daiichi Sankyo, Organon, Bayer, Boehrinher-Ingleheim, Chiesi, 
      Menarini, Raisio Group, Zydus, Menarini, and Wondr Medical, Member in advisory 
      board of Amgen, Bristol Myers Squibb, Chiesi, Menarini, Bayer, 
      Boehrinher-Ingleheim, Daiichi Sankyo and Novartis.
EDAT- 2023/02/04 06:00
MHDA- 2023/03/30 06:11
PMCR- 2023/02/03
CRDT- 2023/02/03 19:52
PHST- 2022/11/23 00:00 [revised]
PHST- 2022/09/09 00:00 [received]
PHST- 2022/12/15 00:00 [accepted]
PHST- 2023/03/30 06:11 [medline]
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/03 19:52 [entrez]
PHST- 2023/02/03 00:00 [pmc-release]
AID - EHF214290 [pii]
AID - 10.1002/ehf2.14290 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2023 Apr;10(2):1372-1384. doi: 10.1002/ehf2.14290. Epub 2023 Feb 
      3.